A-Share Surge: Baili Tianheng Soars 20% on Exclusive Licensing Deal Between Subsidiary SystImmune and Bristol Myers Squibb for BL-B01D1

Gelonghui December 12 | Biokin (688506.SH) surged 20% to RMB 131.11, hitting a record high, with a total market value of RMB 52.58 billion. Biokin announced on December 12 that its wholly-owned subsidiary, SystImmune Inc., had reached an exclusive licensing and cooperation agreement with Bristol-Myers Squibb regarding the BL-B01D1 (EGFR×HER3 bispecific ADC) project. BL-B01D1 is a potential first-in-class EGFR/HER3 bispecific antibody-drug conjugate (ADC). According to the cooperation agreement, the two parties will jointly promote the development and commercialization of BL-B01D1 in the United States; the potential total transaction amount could reach up to USD 8.4 billion.